 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
ALLOS THERAPEUTIC, (ALTH) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
Allos Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of small molecule drugs for cancer treatments. Its three product candidates under development include Efaproxyn, PDX, and RH1. The Efaproxyn is a synthetic small molecule designed to sensitize hypoxic or oxygen-deprived areas of tumors during radiation therapy. It is evaluated as an adjunct to whole brain radiation therapy in a pivotal Phase 3 trial in women with brain metastases originating from breast cancer. PDX is a small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, a folic acid dependent enzyme involved in the building of nucleic acid and other processes. PDX is in a Phase 1/2 single-agent study in patients with nonHodgkin's lymphoma; a Phase 1 combination study with docetaxel in patients with advanced cancer, including nonsmall cell lung cancer (NSCLC); and a Phase 1 single-agent study to determine the maximum tolerated dose of PDX in patients with NSCLC. RH1 is a small molecule chemotherapeutic agent that is bioactivated by the enzyme DT-diaphorase, which is over-expressed in various tumors relative to normal tissue, including lung, colon, breast, and liver tumors. The company was incorporated as HemoTech Sciences, Inc. in 1992 and changed its name to Allos Therapeutics, Inc. in 1994. Allos Therapeutics is headquartered in Westminster, Colorado.
|
|
|
|
|
